Team care of type 2 diabetes mellitus in Taiwan

Wang, Chih‐Yuan; Yu, Neng-Chun; Sheu, Wayne Huey‐Herng; Tsai, Shih-Tzer; Tai, Tong-Yuan

doi:10.1016/s0168-8227(14)70735-1

Cited by 24 publications

(25 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13,14,[16][17][18][19][20] Rates of HbA1c target (<7.0%) attainment were greater with both administered basal insulin treatments than previously reported rates with oral antihyperglycaemic drugs. [6][7][8][9] However, in Korea, guidelines recommend an HbA1c target of <6.5%, against which the achievement rates reported here are slightly lower than those reported elsewhere. 9 In addition, comparing this study with with the present study.…”

Section: Discussioncontrasting

confidence: 53%

“…[3][4][5] Rates of glycaemic control are low in these Asia Pacific countries, with around one in three patients in China and Taiwan achieving an HbA1c of <7.0% and around one in four patients in Korea achieving an HbA1c of <6.5%. [6][7][8][9] Many people with type 2 diabetes (T2D) may require basal insulin therapy to achieve glycaemic control as their disease progresses.…”

Section: Based On the 2017 International Diabetes Federation Global Dmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin‐naïve people with type 2 diabetes: The EDITION AP randomized controlled trial

Kang

Dong

et al. 2019

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim To compare the efficacy and safety of Gla‐300 versus Gla‐100 in insulin‐naïve people with type 2 diabetes in Asia Pacific. Materials and Methods In this open‐label, randomized, active‐controlled, 26‐week study, insulin‐naïve participants with type 2 diabetes inadequately controlled with non‐insulin antihyperglycaemic drugs were randomized (2:1) to Gla‐300 or Gla‐100. The initial daily dose of basal insulin was 0.2 U/kg and was adjusted at least weekly for 8–12 weeks to a target fasting self‐monitored plasma glucose (SMPG) of 4.4–5.6 mmol/L. Results Of the 604 participants randomized, 570 (Gla‐300, n = 375; Gla‐100, n = 195) completed the study. Non‐inferiority of Gla‐300 versus Gla‐100 in HbA1c reduction from baseline to week 26 was confirmed. In the Gla‐300 and Gla‐100 groups, 51.1% and 52.2% of participants achieved the HbA1c target of <7.0% (rate ratio [95% CI]: 0.98 [0.84 to 1.14]) and 19.1% and 21.9% achieved the target without hypoglycaemia during the last 12 weeks of treatment (rate ratio [95% CI]: 0.87 [0.63 to 1.20]). Changes in fasting plasma glucose and 24‐hour average eight‐point SMPG were comparable between groups. Incidence of hypoglycaemia at any time of day was similar between treatment groups at week 26, but incidence of any nocturnal hypoglycaemia was numerically lower with Gla‐300 than Gla‐100 over the initial 12‐week titration period and 26‐week on‐treatment period. Rates of adverse events were similar between groups and low for serious adverse events. Conclusions Glycaemic control of Gla‐300 is non‐inferior to Gla‐100 with a similar or lower incidence and proportion of hypoglycaemia in people with type 2 diabetes in Asia Pacific, reinforcing the results in the global EDITION programme.

show abstract

Section: Discussioncontrasting

confidence: 53%

Section: Based On the 2017 International Diabetes Federation Global Dmentioning

confidence: 99%

Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin‐naïve people with type 2 diabetes: The EDITION AP randomized controlled trial

Kang

Dong

et al. 2019

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…This poor control of cardiovascular risk was similar across all participating countries, and was consistent with low goal attainment rates reported previously for studies conducted predominantly in North America and Western Europe. [5][6][7][8][9][10][11][12][13] As ICLPS was performed in countries and geographical regions often overlooked by other international studies, these findings indicate that poor control of multiple risk factors is a worldwide problem.…”

Section: Discussionmentioning

confidence: 89%

“…[5][6][7][8] Studies in non-Western populations are limited, but generally report multifactor control rates of up to $10%. [10][11][12] Variations between countries have not been studied extensively; however, poor control of risk factors has been implicated in the higher rates of cardiovascular events and mortality observed in lowand middle-income countries (LMICs) compared with high-income countries (HICs), despite the lower riskfactor burden in LMICs. 14 For each patient, multiple factors interact to determine the likelihood of good risk factor control.…”

Section: Introductionmentioning

confidence: 99%

The challenge of multiple cardiovascular risk factor control outside Western Europe: Findings from the International ChoLesterol management Practice Study

Blom

Santos

Daclin

et al. 2019

Eur J Prev Cardiolog

View full text Add to dashboard Cite

Background Comprehensive control of multiple cardiovascular risk factors reduces cardiovascular risk but is difficult to achieve. Design A multinational, cross-sectional, observational study. Methods The International ChoLesterol management Practice Study (ICLPS) investigated achievement of European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guideline low-density lipoprotein cholesterol (LDL-C) targets in patients receiving lipid-modifying therapy in countries outside Western Europe. We examined the rate of, and association between, control of multiple risk factors in ICLPS participants with dyslipidaemia, diabetes and hypertension (N = 2377). Results Mean (standard deviation) age of patients was 61.4 (10.4) years; 51.3% were male. Type 2 diabetes was the most common form of diabetes (prevalence, 96.9%). The prevalence of metabolic syndrome was 67.8%, obesity 40.4%, atherosclerotic disease 39.6% and coronary artery disease 33.5%. All patients were at high (38.2%) or very high (61.8%) cardiovascular risk according to ESC/EAS guidelines. Body mass index (BMI) was <25 kg/m2 in 20.3% of patients, 62.8% had never smoked and 25.2% were former smokers. Overall, 12.2% achieved simultaneous control of LDL-C, diabetes and blood pressure. Risk factor control was similar across all participating countries. The proportion of patients achieving individual guideline-specified treatment targets was 43.9% for LDL-C, 55.5% for blood pressure and 39.3% for diabetes. Multiple correspondence analysis indicated that control of LDL-C, control of blood pressure, control of diabetes, BMI and smoking were associated. Conclusion Comprehensive control of multiple cardiovascular risk factors in high-risk patients is suboptimal worldwide. Failure to control one risk factor is associated with poor control of other risk factors.

show abstract

“…This marker shows the average sugar in the blood of a person over the past 3 months (8). The normal level of HbA2c in individuals with normal blood sugar (FPG<100) is less than 5.6%, whereas this value in people with diabetes is more than 5.6% (9). This test is very specialized and sensitive for plasma blood glucose measurement, it has its limitations such as: in individuals who recently lost a lot of blood or have a type of hemoglobinopathies such as sickle cell anemia or hemolytic anemia, its measurement is worthless (10).…”

Section: Introductionmentioning

confidence: 99%

Investigating the effect of atorvastatin drug on HbA1c in patients with myocardial infarction hospitalized in Farshchian Hospital, Hamadan province, Iran, in 2014-2015 (a before-after study)

2019

View full text Add to dashboard Cite

Use of statins reduces the risk of cardiovascular diseases, however, in some studies, contradicting results about statins especially atorvastatin with the risk of diabetes have been reported. The purpose of the present study, was to investigate the effect of atorvastatin drug on HbA1c in patients with myocardial infarction hospitalized in Farshchian Hospital, Hamadan. 60 patients hospitalized in CCU, who were diagnosed with one type of infarction were included in this clinical trial performed as a before-after study. Demographic data were collected using a questionnaire. Before the study and 6 months after the start of the study, the parameters of lipid profile, HbA1c and GFR were measured. Atorvastatin with a dose of 80mg was given to the patients from the beginning of the study for 6 months. The results were analyzed using SPSS. The average age of the male and female patients was 63.83 and 61.11, respectively, which had an insignificant difference. 42 patients (70%) were male and the rest of them were female. Lipid profile results at the end of the study showed improved averages for the parameters, all of which were statistically significant compared to their values at the start of the study. The mean HbA1c increased from 6.19 to 6.43 (P=0.001), the mean fasting blood sugar increased from 103.66 to 110.51 (P=0.001), and the average glomerular filtration rate (GFR) decreased from 69.84 from the start of the study to 67.43 which was statistically significant (P=0.002). Systolic and diastolic blood pressure at the end of the study decreased compared to the start of the study where in systolic blood pressure, this decrease was significant (p=0.003). Based on the results of this study, although the use of atorvastatin reduces lipids, it may create the risk of hyperglycemia in these patients. However, a certain conclusion requires further studies.

show abstract

Team care of type 2 diabetes mellitus in Taiwan

Cited by 24 publications

References 23 publications

Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin‐naïve people with type 2 diabetes: The EDITION AP randomized controlled trial

Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin‐naïve people with type 2 diabetes: The EDITION AP randomized controlled trial

The challenge of multiple cardiovascular risk factor control outside Western Europe: Findings from the International ChoLesterol management Practice Study

Investigating the effect of atorvastatin drug on HbA1c in patients with myocardial infarction hospitalized in Farshchian Hospital, Hamadan province, Iran, in 2014-2015 (a before-after study)

Contact Info

Product

Resources

About